U.S. Markets for Medical
STUDY GOAL AND OBJECTIVES.
This study provides a comprehensive
analysis of available and emerging anti-infective products. Its aim is to
provide a range of information — from detailed product analyses through
industry trends — to quantify and qualify the market for anti-infective
products. Forecasts of product categories and industry trends are provided
for the U.S. prescription and over-the-counter (OTC) markets and, when
available, for international markets. Forecasts and trends are gleaned
from interviews with industry sources as well as from considered
assessment of available and emerging technologies.
REASONS FOR DOING THE STUDY.
The anti-infective market is facing the
greatest technological challenge in its history — a growing resistance
by infective microorganisms to almost all available products. Researchers
are comparing the emerging age of resistance to the pre-antibiotic era
that existed before the discovery of penicillin. The crisis in
anti-infective resistance and the strategies for combating it provide the
primary reason for studying this market and what it will become.
The market for anti-infectives witnessed
declining annual revenue growth during the first half of the 1990s, and is
projected to grow less than 1% annually throughout the forecast period.
This minimal growth is due to two factors — few projected new drug
launches and a substantial number of branded anti-infective agents losing
patent protection and experiencing competition from lower-priced generic
CONTRIBUTIONS OF THE STUDY AND
This report provides a thorough
background in the anti-infectives market, offering information needed to
understand the current market and to approach the emerging one. It is an
invaluable tool for business planners, acquisitions specialists, licensing
strategists, product managers, market research analysts, investor
consultants, and anyone interested in the anti-infectives market, its
products, its industry participants, and its future.
SCOPE AND FORMAT.
This report on the anti-infectives
market includes prescription human-use antibacterial, anthelmintic,
antifungal, antiprotozoal, and antiviral agents. Vaccines are not
discussed in this report. The base year for the study is 1996. Figures are
based on revenue figures at the manufacturers' level and are projected at
1996 dollar value; that is, inflation is not computed into the projection
Trends were assessed based on projected
sales for new product introductions, increased ratios of generic products
and subsequent declining prices in some categories, projected increases in
the prevalence of certain diseases, and increasing prevalence of
resistance to certain drugs or categories of drugs, among other factors.
Included in this report are forecasts by
product segment from 1996 through 2002, including supporting analyses for
The study is arranged to offer an
overview of the anti-infectives market accompanied by analyses and
forecasts by product type and application. International markets are
discussed, as well as information on industry structure and the regulatory
environment. Profiles of manufacturers of leading anti-infectives and
strategic analyses of emerging companies, as well as products in
development, provide information on placement of current leading
participants within the market.
Information to prepare this study was
derived from interviews with product managers, marketing strategists,
research executives, and others at leading companies in the anti-infectives
industry. Interviews were also conducted with researchers and product
planners at companies that do not yet participate in this market but which
have products in development that are poised to be introduced during the
forecast period. Discussions were also held with government agencies and
regulatory bodies that monitor and/or regulate infectious diseases and
their treatment. Prospectus assessments and searches of secondary material
such as company annual reports and 10Ks, journal articles, government
resources, and data from health care institutions were also conducted.
Information to prepare this report was
obtained from primary interviews with companies; industry analysts; health
care personnel; the National Institute on Allergies and Infectious
Diseases, the Centers for Disease Control and Prevention, and other
government agencies; literature searches; annual reports; 10Ks; and
B-112 U.S. Markets for Medical
Published June 1997
RELATED BCC WORK CREDENTIALS INCLUDING WORK DONE BY OTHER AUTHORS
Report B-104 Rx-to-OTC Switches
Report B-108 Bulk Pharmaceutical Actives
Report C-058R Generic Prescription Drugs
Report C-092 Medical Anti-Infective
Report C-170 Emerging Markets for AIDS
Vaccines and Drugs
Data and analysis provided courtesy of
BUSINESS COMMUNICATIONS COMPANY, INC., 25 Van Zant Street, Norwalk, CT
06855, Telephone: (203) 853-4266; ext. 309, Email: firstname.lastname@example.org